Fountainhead Investment Partners, a San Antonio-based venture capital firm, has made an investment in Nvision Biomedical Technologies. Terms of the transaction were not disclosed.

Nvision, founded in 2013, provides surgeons implants that are paired with instrumentation and biologics to simplify and improve surgery procedures and help patients get back to their quality of life.

“In just a few years, Nvision has made significant strides as a manufacturer of spine systems,” said Brian Kieser, Managing Partner of Fountainhead Investment Partners. “We are excited about the innovation the company has in development as well as the opportunities for growth in new practice areas. Our investment will assist with launching the next line of products into the market.”

Nvision has developed and manufactured several products that received FDA clearance in Fall 2014 and 2016, including four interbody fusion systems ­– the nv line, and one anterior cervical plate system – the tangis® line. The interbody devices have multiple footprints to adapt to the general shape of the vertebral endplates. Each set is available in a variety of heights to accommodate patient variability. Additionally, Nvision offers a portfolio of human tissue allograft products including patches, fluids, demineralized bone, and sport medicine grafts.

Nvision has several new products in the pipeline at multiple phases of development including testing, FDA submissions, and FDA clearance awaiting market launch.

Fountainhead Investment Partners is a venture capital firm, based in San Antonio, Texas, that invests in early-stage companies. Fountainhead was originally founded as an angel fund in 2014 by a group of successful healthcare entrepreneurs with a vision to connect advancing technologies to solve some of medicines’ most complex issues.

In 2015, Fountainhead transitioned to a venture capital firm, with initial funds focused on companies that are accessing innovative technologies from all industries and applying them to the science of medicine with the intention of disrupting the industry while also advancing patient care. Fountainhead makes portfolio investments ranging from $250,000 to $1.5 million.